What are the key non-GAAP adjustments made to Pfizer's 2002 pharmaceutical revenue?

Pfizer adjusted its 2002 human pharmaceutical revenue by excluding the effect of the 2001 harmonization of an accounting methodology for Medicaid discounts and contract rebate accruals. When further excluding the impact of foreign exchange, the revenue growth was presented on a comparable basis for prior periods.

What is the significance of Pharmacia Corporation's financial statements being included in this filing?

This filing provides Pharmacia's historical financial statements as an exhibit because Pfizer completed its acquisition of Pharmacia on April 16, 2003. This allows investors to review Pharmacia's financial performance and position prior to its full integration into Pfizer.

What are the pro forma combined financial statements for Pfizer and Pharmacia?

The unaudited pro forma condensed combined financial statements present the combined financial results of Pfizer and Pharmacia as if the merger had occurred on January 1, 2003. These statements are adjusted for the effects of the merger, such as purchase accounting adjustments and the elimination of intercompany transactions, to provide an estimated view of the combined company's performance.

Does this filing provide updated guidance or outlook for Pfizer?

This filing is primarily an 8-K reporting historical financial information and reconciliations of non-GAAP measures. It does not contain forward-looking guidance or an updated business outlook for Pfizer.

PFE 8-K SEC Disclosure — Oct 14, 2003

Summary

This 8-K filing from Pfizer Inc. primarily serves to provide reconciliations for non-GAAP financial measures used in its 2002 Annual Report (Form 10-K) and to present historical financial information for Pharmacia Corporation following its merger with Pfizer. For Pfizer, the filing clarifies its reported human pharmaceutical revenues, adjusting for accounting methodology harmonization and foreign exchange impacts. It also details adjustments to its effective tax rate by excluding significant items and merger-related costs. For Pharmacia, the filing presents its unaudited financial statements for the first quarter of 2003, balance sheet as of March 31, 2003, and comparative data from the prior year. It also includes unaudited pro forma condensed combined financial statements for the six months ended June 29, 2003, reflecting the merger with Pfizer. Investors should note the significant details on Pharmacia's financials prior to the full integration with Pfizer, as well as the pro forma combined figures to understand the post-merger entity's potential financial profile.

Key Highlights

1Pfizer provides reconciliations for non-GAAP financial measures related to its 2002 human pharmaceutical revenues, showing adjusted growth rates excluding accounting harmonization and foreign exchange effects.
2The filing clarifies Pfizer's effective tax rate for continuing operations, excluding certain significant items and merger-related costs for 2002 and 2001.
3Historical financial statements for Pharmacia Corporation, including statements of earnings, cash flows, and a balance sheet as of March 31, 2003, are presented as an exhibit.
4The merger between Pfizer and Pharmacia, effective April 16, 2003, is a significant event detailed within the filing, with Pharmacia's financial statements presented on a standalone basis prior to full integration.
5Unaudited pro forma condensed combined financial statements for the six months ended June 29, 2003, are provided to show the combined financial picture of Pfizer and Pharmacia post-merger.
6The pro forma statements indicate significant adjustments related to purchase accounting, including the elimination of intercompany transactions and the recording of fair value step-ups for assets and liabilities.

PFIZER INC 8-K Report (Oct 14, 2003)

Summary

Key Highlights

Frequently Asked Questions